GH pulse amplitude does not return to pre-treatment levels immediately after stopping sermorelin. The pituitary resensitization that develops over 6 months persists for weeks to months after the last injection in most patients.
There is no single correct answer for how long to stay on sermorelin. The appropriate protocol duration depends on the clinical goal, the IGF-1 response at 90 days, and whether the patient is pursuing restoration or maintenance. This guide describes the standard evaluation windows, the case for continuous versus cycling protocols, and what to expect when stopping.
- 503B outsourcing facilities are FDA-regulated and held to cGMP standards like commercial drug manufacturers
- 503A pharmacies compound to individual prescriptions and are regulated by state boards of pharmacy
- USP 797 (sterility) and USP 85 (endotoxicity) are the standards that apply to injectable compounded peptides
- A Certificate of Analysis should be available on request for every batch
- Reconstituted sermorelin must be refrigerated and used before the beyond-use date
Minimum Protocol Duration: Why 6 Months
Most controlled trials of GHRH-analog therapy run 5 to 6 months (Khorram et al. 1997 [1]: 5-month trial; Stanley 2015 tesamorelin [2]: 6-month trial). The clinical goals most patients start sermorelin for, including visceral fat reduction and lean mass support, were seen at the 6-month assessment in tesamorelin trials. A 90-day IGF-1 retest is the typical interim checkpoint for assessing dose response.
| Protocol phase | Duration | What is being achieved |
|---|---|---|
| Initiation | Weeks 1 to 8 | Pituitary resensitization, early sleep changes |
| Early response | Months 2 to 3 | IGF-1 rises toward therapeutic range, energy improvement |
| 90-day evaluation | Month 3 | First dose assessment; adjust if needed |
| Therapeutic window | Months 3 to 6 | Body composition changes accumulate |
| 6-month assessment | Month 6 | Full protocol evaluation; decide to continue or pause |
Continuous Protocol vs. Cycling
A continuous protocol means daily sermorelin administration without a scheduled break. A cycling protocol involves periods on the protocol alternated with periods off, typically 3 months on followed by 1 to 2 months off, or 6 months on followed by 2 to 3 months off.
The clinical rationale for cycling is pituitary receptor sensitivity. Continuous GHRH stimulation over very long periods may reduce the pituitary's responsiveness to sermorelin. Cycling allows the receptor population to reset during the off period. In practice, the evidence for receptor downregulation with sermorelin at standard doses is limited. Most physicians who prescribe long-term protocols use continuous dosing with annual IGF-1 monitoring rather than formal cycling.
What Happens When You Stop
When sermorelin is stopped, the pituitary does not immediately return to its pre-treatment GH output. The resensitization that occurred over the first 3 to 6 months persists for weeks to months after the last injection in most patients. IGF-1 will gradually return toward the pre-treatment baseline, but the rate varies by individual.
- Sleep quality changes: typically the first benefit to diminish, usually within 4 to 8 weeks
- IGF-1 decline: gradual, over 2 to 4 months; rate varies by pre-treatment baseline and age
- Body composition: maintained if exercise and dietary habits are preserved; no rapid reversal
- Energy and recovery: subjective decline typically reported 6 to 10 weeks after stopping
Maintenance Protocols After the Initial 6 Months
Patients who complete a 6-month protocol and want to maintain the IGF-1 improvement have two options: continue at the current dose or reduce to a maintenance dose of 50 to 100 mcg per night. A maintenance dose sustains IGF-1 near the therapeutic range at lower cost and with a reduced side effect profile. Annual IGF-1 monitoring is appropriate for patients on maintenance dosing.
Patients who stop after 6 months and whose symptoms return within 3 to 6 months are candidates for a second full-dose protocol. The pituitary resensitization from the first protocol typically makes the second protocol faster to produce a response than the first.
Long-Term Use: What Is Known
Long-term continuous sermorelin use has not been studied in large controlled trials. The original FDA-approved sermorelin (Geref) was used in pediatric patients for up to 18 months without documented pituitary suppression or downregulation at standard doses. This is consistent with the somatostatin feedback mechanism, which prevents the pituitary from becoming dependent on GHRH stimulation. The feedback axis remains intact throughout the protocol and does not require external stimulation to maintain normal GH output after sermorelin is stopped.
Bottom Line
The minimum meaningful protocol duration is 6 months. Most patients benefit from continuing through month 12 if the 6-month IGF-1 assessment shows the dose is working. Maintenance dosing at 50 to 100 mcg nightly is appropriate for patients who want to sustain IGF-1 improvement at lower intensity after the initial therapeutic protocol. There is no clinical requirement to cycle sermorelin at standard doses, though annual IGF-1 monitoring is appropriate for patients on any long-term protocol.
Frequently Asked Questions
Is it safe to take sermorelin long-term?
Long-term sermorelin use does not have established safety data beyond 12 to 24 months in controlled settings. However, sermorelin's mechanism, stimulating the pituitary rather than replacing GH, and the intact somatostatin feedback axis make prolonged use less concerning than long-term exogenous HGH. Annual IGF-1 monitoring is the standard for patients on extended protocols. The physician should confirm IGF-1 remains in the age-appropriate therapeutic range, not elevated beyond it.
What happens when you stop sermorelin?
IGF-1 begins declining toward pre-treatment baseline within weeks of the last injection. The pituitary resensitization that developed over the protocol gradually reverses over 1 to 3 months. Sleep quality, body composition improvements, and energy benefits typically regress but do so gradually. Patients who stop after a 6-month protocol generally retain some benefit for several months before returning to baseline. There is no acute withdrawal syndrome associated with stopping sermorelin.
Do you need to cycle sermorelin?
Cycling sermorelin at standard doses (100 to 200 mcg nightly) is not clinically required. The pituitary does not develop tolerance to GHRH stimulation at standard therapeutic doses. Some patients and physicians prefer a cycling approach for practical reasons, but this is not supported by evidence as clinically superior to continuous dosing. Continuous low-dose maintenance is a medically sound approach for patients with long-term GH decline.
How do you know when you no longer need sermorelin?
Regular IGF-1 monitoring provides the objective answer. If IGF-1 normalizes into the upper half of the age-adjusted reference range and remains there consistently across multiple draws, and symptoms have resolved, reducing to a maintenance dose or stopping is a clinical option. The decision to stop should be driven by lab data and patient response, not time on protocol alone. Some patients with significant age-related GH decline require indefinite maintenance dosing.
References
- Endocrine and metabolic effects of long-term administration of GHRH-(1-29)-NH2 in age-advanced men and women JCEM, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Effects of Growth Hormone Releasing Hormone on Visceral Fat (6-month tesamorelin trial) Growth Hormone & IGF Research, 2015. PMC4324360. https://pmc.ncbi.nlm.nih.gov/articles/PMC4324360/
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs, 1999. PMID: 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. PMID: 18046908. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
